<DOC>
	<DOCNO>NCT00605397</DOCNO>
	<brief_summary>The purpose study learn new study agent work inside body . The study agent protein call 64Cu-trastuzumab . This radioactive tracer develop MSKCC target HER2 protein cancer cell . A radioactive tracer small amount radioactive dye follow something else radioactive In study study agent , 64Cu-trastuzumab , tracer 's follow trastuzumab ( Herceptin™ ) . By give tracer treatment trastuzumab ( Herceptin™ ) , able use PET scan show u part body tumor sit Herceptin go . This help u understand good Herceptin work body fight cancer .</brief_summary>
	<brief_title>PET Imaging With Cu-64 Labeled Trastuzumab HER2+ Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Registered patient MSKCC Age ≥18 year Patients HER2+ metastatic breast cancer ( either 3+ immunohistochemistry evidence gene amplification ( &gt; 2.0 ) fluorescence situ hybridization ( FISH ) ) Measurable evaluable disease Currently take commence treatment trastuzumab dose schedule 2 mg/kg weekly 6 mg/kg every three week , per standard care Karnofsky Performance Score ≥ 60 Signed inform consent Previous Grade 3 high allergic reaction trastuzumab result discontinuation trastuzumab therapy Claustrophobia/pain leading inability lie still duration scan procedure . Pregnancy Test perform female patient childbearing potential within 24hrs administration radioactive material . Inability provide write informed consent . Patients liver metastasis site distant disease Patients known sensitivity contraindication Herceptin .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Cu-64 LABELED TRASTUZUMAB</keyword>
</DOC>